Home/Filings/4/A/0001104659-17-074883
4/A//SEC Filing

PEHL MICHAEL F. 4/A

Accession 0001104659-17-074883

CIK 0000722830other

Filed

Dec 21, 7:00 PM ET

Accepted

Dec 22, 4:39 PM ET

Size

9.3 KB

Accession

0001104659-17-074883

Insider Transaction Report

Form 4/AAmended
Period: 2017-12-07
PEHL MICHAEL F.
DirectorPresident and CEO
Transactions
  • Award

    Stock Options (right to buy)

    2017-12-07+320,139320,139 total
    Exercise: $11.86Exp: 2024-12-07Common Stock, par value $0.01 per share (320,139 underlying)
  • Award

    Stock Options (right to buy)

    2017-12-07+119,237119,237 total
    Exercise: $11.86Exp: 2024-12-07Common Stock, par value $0.01 per share (119,237 underlying)
Footnotes (4)
  • [F1]The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.
  • [F2]The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 151,678 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $23.72 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 168,461 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $35.58 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date.
  • [F3]If the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, and to the extent such performance-based vesting criteria is subsequently attained, the applicable tranche of stock options may vest on the date such criteria is met.
  • [F4]The purpose of this amendment is to correct the number of shares reported in Table II, Column 5, Column 7 and Column 9.

Documents

1 file

Issuer

IMMUNOMEDICS INC

CIK 0000722830

Entity typeother

Related Parties

1
  • filerCIK 0001677939

Filing Metadata

Form type
4/A
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 4:39 PM ET
Size
9.3 KB